Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort
Authors:
- Annemiek DolsADAnnemiek Dols
- Cora J. KerssensCKCora J. Kerssens
- Niels D. PrinsNPNiels D. Prins
- Christiane MöllerCMChristiane Möller
- Sigfried SchouwsSSSigfried Schouws
- Frederik BarkhofFBFrederik Barkhof
- Bart N.M. van BerckelBBBart N.M. van Berckel
- Charlotte E. TeunissenCTCharlotte E. Teunissen
- Wiesje M. van der FlierWFWiesje M. van der Flier
- Philip ScheltensPSPhilip Scheltens
- Sietske A.M. SikkesSSSietske A.M. Sikkes
- 17 October 2015
- journal article
- research article
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 41 (1-2) , 16-26
Abstract
Background: The criteria for behavioral variant frontotemporal dementia (bvFTD) incorporate MRI and [18F]-FDG-PET. Cerebrospinal fluid (CSF) analysis is merely advised for excluding Alzheimer's disease. Aims: We aimed to assess the impact of biomarkers on diagnostic certainty and contingent changes of bvFTD diagnosis within the clinically relevant neuropsychiatric differential diagnosis of subjects with a late-onset frontal lobe syndrome (LOF). Methods: We included 137 patients with LOF, aged 45-75 years, 72% males. Biomarker disclosure was considered contributing after any substantial difference in diagnostic certainty or a diagnostic change. Percentages of contributing biomarkers were compared between three major diagnostic groups (bvFTD, psychiatry, other neurological disorders). Certainty levels in stable diagnostic groups were compared to those with a diagnostic change. Results: Biomarkers contributed in 53, 60 and 41% of the LOF patients for MRI, [18F]-FDG-PET and CSF, respectively. Biomarkers changed the diagnosis in 14% of cases towards bvFTD and in 13% from bvFTD into an alternative. Those that changed had a lower level of a priori diagnostic certainty compared to stable diagnoses. Conclusion: Our study not only supports the widely accepted use of MRI and [18F]-FDG-PET in diagnosing or excluding bvFTD, but also shows that CSF biomarkers aid clinicians in the diagnostic process.Keywords
This publication has 47 references indexed in Scilit:
- Cerebrospinal Fluid Tau Levels Predict Prognosis in Non-Inherited Frontotemporal DementiaNeurodegenerative Diseases, 2013
- Neuropsychiatric Profiles in DementiaAlzheimer Disease & Associated Disorders, 2011
- A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTDNeuron, 2011
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementiaBrain, 2011
- Visual assessment of posterior atrophy development of a MRI rating scaleEuropean Radiology, 2011
- The Diagnostic Challenge of Psychiatric Symptoms in Neurodegenerative DiseaseThe Journal of Clinical Psychiatry, 2011
- Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an updateActa Neuropathologica, 2009
- CSF biomarkers in frontotemporal lobar degeneration with known pathologyNeurology, 2008
- Early-Onset Dementia: Frequency and Causes Compared to Late-Onset DementiaDementia and Geriatric Cognitive Disorders, 2006
- Differentiation of Geriatric Major Depression From Alzheimer’s Disease With CSF Tau Protein Phosphorylated at Threonine 231American Journal of Psychiatry, 2003